LEAWOOD, Kan., June 11, 2019 /PRNewswire/ -- Aratana
Therapeutics, Inc. (Nasdaq: PETX), a pet therapeutics company
focused on the development and commercialization of innovative
therapeutics for dogs and cats, today announced the U.S. Food and
Drug Administration's Center for Veterinary Medicine (CVM) approved
an additional vial size (10 mL) for NOCITA® (bupivacaine
liposome injectable suspension). NOCITA is currently available in a
20 mL vial size and Aratana continues to anticipate commercial
availability of the NOCITA 10 mL vial by fall 2019.
"Since its launch in 2016, Nocita has drastically changed
veterinary multimodal pain management protocols because it safely
and effectively controls pain in patients for up to 72 hours
following certain canine and feline surgeries," states Dr.
Ernst Heinen, Chief Development
Officer for Aratana Therapeutics. "Ultimately, we believe a smaller
vial size may allow for expanded use and improve the level of care
veterinarians provide for certain painful surgeries."
NOCITA is FDA-approved for single-dose infiltration into the
surgical site to provide local post-operative analgesia for cranial
cruciate ligament surgery in dogs and as a peripheral nerve block
to provide regional post-operative analgesia following
owner-elected onychectomy in cats. For those interested in learning
more about NOCITA, please visit nocita.aratana.com.
About Aratana Therapeutics
Aratana Therapeutics is a
pet therapeutics company focused on developing and commercializing
innovative therapeutics for dogs and cats. Our mission is to
successfully develop and deliver best-in-class therapeutics,
provide comprehensive service to veterinarians and serve as a
collaborator of choice for human and animal health companies. We
believe our therapeutics are highly differentiated, resolve
recognizable needs in compelling markets and have therapeutic
profiles superior to the standard of care. For more information,
please visit www.aratana.com.
IMPORTANT SAFETY INFORMATION
NOCITA®
(bupivacaine liposome injectable suspension) is for local
infiltration injection in dogs only. Do not use in dogs younger
than 5 months of age, that are pregnant, lactating or intended for
breeding. Do not administer by intravenous or intra‐arterial
injection. Adverse reactions in dogs may include discharge from
incision, incisional inflammation and vomiting. Avoid concurrent
use with bupivacaine HCl, lidocaine or other amide local
anesthetics. Please see the full Prescribing
Information for more detail.
NOCITA® (bupivacaine liposome injectable suspension)
is for use as a peripheral nerve block in cats only. Do not use in
cats younger than 5 months of age, that are pregnant, lactating, or
intended for breeding. Do not administer by intravenous or
intra‐arterial injection. Adverse reactions in cats may include
elevated body temperature, infection or chewing/licking at the
surgical site. Avoid concurrent use with bupivacaine HCl, lidocaine
or other amide local anesthetics. Please see the
full Prescribing Information for more detail.
Forward-Looking Statements Disclaimer
This press
release contains forward-looking statements (as that term is
defined in the Private Securities Litigation Reform Act of 1995)
and reflects Aratana's current beliefs. However, as with any
pharmaceutical product, there are substantial risks and
uncertainties in the process of development and commercialization.
Among other things, all statements contained in this press release
that do not relate to matters of historical fact should be
considered forward-looking statements and there can be no guarantee
with respect to our ability to bring innovative therapeutics to the
market; steps necessary for and timing of regulatory submissions
and approvals of therapeutic candidates; study, development and
commercialization of therapeutics or therapeutic candidates,
including without limitation the potential use and timing of
availability of the 10 mL vial size of NOCITA; ongoing efforts to
commercialize ENTYCE and NOCITA; increased market recognition of
and demand for our therapeutics; and statements regarding the
Company's efforts, plans and opportunities, including, without
limitation, advancing our therapeutic candidates and offering
innovative therapeutics that help manage pet's medical needs safely
and effectively and that result in longer and improved quality of
life for pets. For further discussion of these and other
risks and uncertainties, see Aratana's most recent Form 10-K and
Form 10-Q filings with the United States Securities and Exchange
Commission. These and other important factors discussed in
Aratana's SEC filings could cause actual results to differ
materially from those indicated by the forward-looking statements
made in this press release. Any such forward-looking statements
represent estimates or statements as of the date of this press
release. While we may elect to update such forward-looking
statements at some point in the future, we disclaim any obligation
to do so, even if subsequent events cause our views to change,
except as required under applicable law. These forward-looking
statements should not be relied upon as representing our views as
of any date subsequent to the date of this press release.
Contacts
For investor inquires:
Rhonda Hellums
rhellums@aratana.com
(913) 353-1026
For media inquiries:
Rachel Reiff
rreiff@aratana.com
(913) 353-1050
View original content to download
multimedia:http://www.prnewswire.com/news-releases/aratana-therapeutics-granted-fda-approval-of-nocita-bupivacaine-liposome-injectable-suspension-10-ml-vial-300865670.html
SOURCE Aratana Therapeutics